[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100635285":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":50,"collaborators":52,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":59,"acronym":20,"eligibilityCriteria":60,"healthyVolunteers":57,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":20,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":75,"overallStatus":30,"whyStopped":20,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"ABLE Human Motion S.L.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Gait training with ABLE Exoskeleton + Functional Electrical Stimulation (ABLE FES)","EXPERIMENTAL","Participants will undergo 8 rehabilitation sessions over 4-5 weeks using the ABLE Exoskeleton with Functional Electrical Stimulation integration (ABLE FES). Each session will last approximately 60 minutes and include donning\u002Fdoffing, gait training, and functional assessments. Electrode placement and stimulation parameters will be adapted to the participant's pathology (spinal cord injury, acquired brain injury, or multiple sclerosis). Participants will also complete baseline, post-training, and follow-up assessments.",[13],"Device: ABLE Exoskeleton with Functional Electrical Stimulation (ABLE FES)",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DEVICE","ABLE Exoskeleton with Functional Electrical Stimulation (ABLE FES)","A robotic lower-limb exoskeleton integrated with functional electrical stimulation (ABLE FES) used for gait rehabilitation training.",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Peter Lackner, Dr.","CONTACT","+43 681 207 41241","peter@tech2people.at",[28],{"facility":29,"status":30,"city":31,"state":32,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"therapy2people GmbH","RECRUITING","Vienna","State of Vienna","1220","Austria","AT",{"type":37,"coordinates":38},"Point",[39,40],16.37208,48.20849,{"lat":40,"lon":39},[43,47],{"name":44,"role":24,"phone":45,"phoneExt":20,"email":46},"Philipp Bruchbacher","+43 681 20741241","philipp@tech2people.at",{"name":48,"role":24,"phone":45,"phoneExt":20,"email":49},"Dennis Veit","dennis@tech2people.at",{"type":51,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR",[53],{"name":29,"class":54},"UNKNOWN","100635285","clinical-investigation-to-validate-the-safety-and-performance-of-integrating-functional-electrical-stimulation-into-the-able-exoskeleton-100635285",false,"NCT07550699","Clinical Investigation to Validate the Safety and Performance of Integrating Functional Electrical Stimulation Into the ABLE Exoskeleton","Inclusion Criteria:\n\n* 18 to 80 years old\n* Diagnosis of acquired brain injury, spinal cord injury (neurological level between C5 and L2, AIS B to AIS D), or multiple sclerosis\n* Currently undergoing physiotherapy treatment, either as an inpatient or outpatient at the investigating center\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Significant osteoporosis that may increase the risk of fracture\n* Unresolved fractures in the pelvis or limbs, or a history of fragility fractures in the lower limbs within the past 2 years\n* Spinal instability (or use of spinal orthoses, unless medically approved)\n* Deterioration \\>3 points of the total in the motor score of the International Standards for the Neurological Classification of Spinal Cord Injury (ISNCSCI) in the last 4 weeks. Loss of sensation and\u002For motor activity above the level of injury detected that has not been evaluated by a doctor.\n* Severe spasticity: Level 4 on the Modified Ashworth Scale\n* Orthostatic hypotension: Inability to tolerate at least 10 minutes in an upright position\n* Uncontrolled autonomic dysreflexia\n* Medical instability\n* Unstable cardiovascular condition, hemodynamic instability, untreated hypertension (SBP \\> 140 mmHg, DBP \\> 90 mmHg), deep vein thrombosis (DVT), or uncontrolled autonomic dysreflexia\n* Severe comorbidities, including any condition deemed inappropriate by the investigator for using the ABLE Exoskeleton or for completing the study\n* Pressure ulcers Grade I or higher (as defined by the European Pressure Ulcer Advisory Panel - EPUAP) in areas that will be in contact with the device\n* Anthropometric measurements incompatible with the ABLE Exoskeleton, specifically height outside the 1.5-1.9 m range or weight exceeding 100 kg\n* Anatomical constraints (such as leg length differences, users unable to position themselves inside the device) that are incompatible with the device\n* Range of motion restrictions preventing normal gait or sit-to-stand transitions, including: Ankle: ability to achieve at least neutral (0°) position; Knee: ability to extend to at least -10°; Hip: bilateral hip flexion of at least 100° and extension of at least 0°\n* Heterotopic ossification\n* Pregnant or breastfeeding women\n* Cognitive impairment that results in the inability to follow simple instructions, particularly psychological or cognitive problems that do not allow a participant to follow study procedures\n* Requires assisted ventilation.\n* Scoliosis \\>40-50º Cobb angle.\n* Presence of pacemakers, defibrillators, or other non-compatible electronic implants.\n* Open wounds, infections, or active irritation at the electrode placement sites.\n* Severe dermatological conditions in the stimulation area.\n* Uncontrolled active epilepsy.\n* Malignant tumors in the area of application.\n* Severe loss of sensation in the areas where electrodes are to be placed.\n* Medical conditions where electrical stimulation is contraindicated by physician recommendation.\n* Inability to communicate pain, discomfort, or adverse reactions during stimulation.\n* Venous thrombosis, thrombophlebitis, or severe arterial obstruction.\n* Chronic venous insufficiency with significant varicosities.\n* Hemophilia.\n* Ongoing infectious process or fever.\n* Presence of metallic implants in the flow area between the electrodes","ALL","18 Years","80 Years",{"count":65,"type":66},15,"ESTIMATED","INTERVENTIONAL",[69],"NA","The primary objective of this study is to validate the safety and clinical performance of the ABLE Exoskeleton with integrated Functional Electrical Stimulation (ABLE FES) in individuals with neurological conditions that impair gait, including spinal cord injury, acquired brain injury, and multiple sclerosis.\n\nThe secondary objective is to collect preliminary data on the potential clinical and psychosocial benefits of combining robotic gait assistance with electrical stimulation.",[72,73,74],"Acquired Brain Injury (Including Stroke)","Spinal Cord Injury","Multiple Sclerosis",[76,77,78,79,73,74,80,81,82],"Gait training","Wearable exoskeleton","Acquired Brain Injury","Lower-limb exoskeleton","Functional Electrical Stimulation (FES)","Robotic exoskeleton","Hybrid exoskeleton-FES system","2026-04-22",{"date":85,"type":86},"2026-04-24","ACTUAL",{"date":88,"type":86},"2026-04-20",{"date":90,"type":66},"2026-08-12",{"name":5,"class":6},1]